About Xylopia
Xylopia is a Healthcare company. It operates as a drug development and dosage form research services in pharmaceuticals. The company has 111 employees. Its Indian entity Xylopia Labs Private Limited reported revenue of ₹35.06 Cr. Xylopia offers products and services including Dosage Form Development and Formulation Research. Its focus areas include Biotechnology, Regulatory Services, Formulation Programs and Pharmaceuticals.
Company details
Xylopia is recognized as an integrated provider of drug development solutions, where full-service research and development in dosage forms are offered to global pharmaceutical companies. Commitments to client programs are supported by carefully planned infrastructure and equipment, along with a team of experienced members who ensure high-quality deliverables in formulation and regulatory efforts. Partnerships are established to facilitate competitive-level development, emphasizing value addition through technical competence and reliable services.
- Employees 111
- SectorsHealthcare
- Email••••••••
- Legal Name Xylopia Labs Private Limited
- Date of Incorporation 06 Feb, 2019
- Jurisdiction Ahmedabad, Gujarat, India
- Annual Revenue₹35.06 Cr
FY 2025 · +8% YoY
- Net Profit₹1.71 Cr
FY 2025 · 5% margin
- EBITDA₹5.44 Cr
FY 2025 · 16% margin
- Employee Count111
Associated legal entities of Xylopia
Xylopia operates through Xylopia Labs Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Xylopia Labs Private Limited CIN U73100GJ2019PTC106443 | Active | 06 Feb 2019 | Ahmedabad, Gujarat | ₹35.1 Cr | 111 | 2 | View details |
Products & Services of Xylopia
Xylopia offers a comprehensive portfolio of products and services, including Dosage Form Development and Formulation Research.
Dosage form development services are offered in collaboration with pharmaceutical companies for regulatory programs.
Formulation research services are provided to support drug development initiatives through expert team efforts.
Board of directors of Xylopia Labs Private Limited (Xylopia)
Xylopia Labs Private Limited is the primary company behind Xylopia. The board of Xylopia Labs Private Limited currently have 2 directors; the longest-serving is Vijay Vinod Patel, appointed in 2019.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vijay Vinod Patel DIN 01805816 | Director | 06 Feb 2019 | 7 yrs 8 mo | Xylopia Labs Private Limited |
| Mukesh Raojibhai Patel DIN 00032104 | Director | 06 Feb 2019 | 7 yrs 8 mo | Xylopia Labs Private Limited |
Financials of Xylopia
Figures of Xylopia Labs Private Limited, the primary company behind Xylopia, for FY 2025. Revenue was ₹35.06 Cr (+8% year on year). Net profit was ₹1.71 Cr (5% margin). EBITDA was ₹5.44 Cr (16% margin). Revenue has grown at a compounded annual rate of +5% over three years and +4% over five years.
- ₹35.06 CrRevenue · FY 2025 · +8% YoY
- ₹1.71 CrNet profit · 5% margin
- ₹5.44 CrEBITDA · 16% margin
- ₹1 LakhPaid-up capital
- 111Employees (provident fund records)
- +5%Revenue CAGR, 3 years
- +4%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Xylopia Labs Private Limited are on its company page.
Detailed financial statements for Xylopia
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
10 companies that operate in the same segment as Xylopia (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Xylopia
Xylopia has 111 employees.
The primary company behind Xylopia, Xylopia Labs Private Limited, reported revenue of ₹35.06 Cr for FY 2025, up 8% year on year.
Xylopia is recognized as an integrated provider of drug development solutions, where full-service research and development in dosage forms are offered to global pharmaceutical companies. Commitments to client programs are supported by carefully planned infrastructure and equipment, along with a team of experienced members who ensure high-quality deliverables in formulation and regulatory efforts. Partnerships are established to facilitate competitive-level development, emphasizing value addition through technical competence and reliable services.
Xylopia offers Dosage Form Development and Formulation Research.
Xylopia operates through Xylopia Labs Private Limited.
The legal entities of Xylopia currently have 2 directors, including Vijay Vinod Patel, Mukesh Raojibhai Patel.